His primary areas of investigation include Internal medicine, Immunology, Lupus erythematosus, Rheumatology and Placebo. His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology and Surgery. His work carried out in the field of Immunology brings together such families of science as Tolerability and Disease.
The various areas that Daniel J. Wallace examines in his Lupus erythematosus study include Anti-nuclear antibody, Systemic lupus erythematosus, Lupus nephritis and Chemotherapy. His research integrates issues of Systemic disease, Physical therapy, Biomarker and Clinical significance in his study of Rheumatology. His studies deal with areas such as Tabalumab, Belimumab, Adverse effect and Randomized controlled trial as well as Placebo.
Daniel J. Wallace mainly focuses on Internal medicine, Immunology, Lupus erythematosus, Systemic lupus erythematosus and Rheumatology. The Internal medicine study combines topics in areas such as Gastroenterology and Placebo. In his study, Cyclophosphamide is strongly linked to Lupus nephritis, which falls under the umbrella field of Immunology.
His Lupus erythematosus study combines topics in areas such as Surgery, MEDLINE, Belimumab, Disease and Severity of illness. His Systemic lupus erythematosus research is multidisciplinary, relying on both Dermatology and Intensive care medicine. His Rheumatology research incorporates themes from Anti-nuclear antibody and Physical therapy.
His primary areas of study are Internal medicine, Lupus erythematosus, Systemic lupus erythematosus, Rheumatology and Immunology. His Internal medicine research integrates issues from Gastroenterology, Placebo and Anti-nuclear antibody. His work deals with themes such as Monoclonal, Young adult, Dermatology, Disease and Severity of illness, which intersect with Lupus erythematosus.
The study incorporates disciplines such as Medical record, Prospective cohort study, Quality of life and Hazard ratio in addition to Systemic lupus erythematosus. His Rheumatology study combines topics in areas such as Cohort study, MEDLINE, Autoantibody, Rheumatism and Frailty Index. Within one scientific family, Daniel J. Wallace focuses on topics pertaining to Gene expression under Immunology, and may sometimes address concerns connected to Interferon and Janus kinase.
His main research concerns Internal medicine, Lupus erythematosus, Systemic lupus erythematosus, Rheumatology and Young adult. His studies link Anti-nuclear antibody with Internal medicine. His Lupus erythematosus research includes themes of Predictive value of tests, Randomized controlled trial, Severity of illness and Monoclonal.
He has researched Systemic lupus erythematosus in several fields, including Quantitative trait locus, Prospective cohort study and Medical record. The various areas that Daniel J. Wallace examines in his Rheumatology study include Autoantibody, Frailty Index and Hazard ratio. The study incorporates disciplines such as Autoimmune disease, Disease, Incidence and Nephritis in addition to Young adult.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.
Michelle Petri;Ana Maria Orbai;Graciela S. Alarcõn;Caroline Gordon.
Arthritis & Rheumatism (2012)
Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus: The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial
Joan T. Merrill;C. Michael Neuwelt;Daniel J. Wallace;Joseph C. Shanahan.
Arthritis & Rheumatism (2010)
American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis
Bevra H. Hahn;Maureen A. McMahon;Alan Wilkinson;W. Dean Wallace.
Arthritis Care and Research (2012)
The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes
Matthew H. Liang;Michael Corzillius;Sang Cheol Bae;Robert A. Lew.
Arthritis & Rheumatism (1999)
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie;Michelle Petri;Omid Zamani;Ricard Cervera.
Arthritis & Rheumatism (2011)
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis
Ellen M. Ginzler;Mary Anne Dooley;Cynthia Aranow;Mimi Y. Kim.
The New England Journal of Medicine (2005)
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Christian E. Antoni;Arthur Kavanaugh;Bruce Kirkham;Zuhre Tutuncu.
Arthritis & Rheumatism (2005)
Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis.
M Linker-Israeli;R J Deans;D J Wallace;J Prehn.
Journal of Immunology (1991)
Dubois' Lupus Erythematosus
Daniel J. Wallace.
A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis.
Dimitrios T. Boumpas;Richard Furie;Susan Manzi;Gabor G. Illei.
Arthritis & Rheumatism (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: